Medication

Treatment with pemafibrate does not reduce the risk for cardiovascular events in people with type 2 diabetes, despite substantial reductions in triglycerides, report the PROMINENT trial investigators.

Moderate- or high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin are the most effective statins for reducing non-high-density lipoprotein cholesterol levels in people with diabetes, study findings indicate.

Study findings published in JAMA Internal Medicine show that treatment initiation with statins is associated with an elevated risk for diabetes progression.

Reasons for ethnic disparities in statin prescribing in UK residents with type 2 diabetes are not clear, but may result in preventable atherosclerotic cardiovascular disease events, research suggests.

The duration of statin therapy in people with type 2 diabetes may be even more important than the intensity or the achieved level of low-density lipoprotein cholesterol for preventing cardiovascular events, research suggests.

People with type 2 diabetes, especially young people, do not receive treatment for hypertension and dyslipidemia in a timely manner, even when they have high cardiovascular risk, study results show.

Canadian clinicians have reported the case of a woman on long-term rosuvastatin treatment who developed rhabdomyolysis within days of starting on canagliflozin.

Listen to our Editorial Board reflecting on their ADA scientific highlights, and its novel virtual format (34:17).

A major study shows that non-high-density lipoprotein levels predict atherosclerosis events over a 30-year timescale.

The potent lipid-lowering effects of the PCSK9 inhibitor evolocumab have been demonstrated in a randomized trial conducted specifically in people with type 2 diabetes.

A population-based study suggests that treatment with a statin may slow the risk for new and worsening retinopathy in patients with diabetes and dyslipidemia.

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

Ganda O. Curr Diab Rep 2018; 18: 126. doi: 10.1007/s11892-018-1087-0

Patti G et al. Nat Rev Cardiol 2018. doi: 10.1038/s41569-018-0080-2

van Stee MF, de Graaf AA, Groen AK. Cardiovasc Diabetol 2018; 17: 94. doi: 10.1186/s12933-018-0738-4

Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5

Blanc-Bisson C et al. Cardiovasc Diabetol 2018; 17: 82. doi: 10.1186/s12933-018-0718-8

Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7

Matsutani D et al. Cardiovasc Diabetol 2018; 17: 73. doi: 10.1186/s12933-018-0717-9